TY - JOUR
T1 - Fucosylated chondroitin sulfate from Isostichopus badionotus alleviates metabolic syndromes and gut microbiota dysbiosis induced by high-fat and high-fructose diet
AU - Li, Shan
AU - Li, Junhui
AU - Mao, Guizhu
AU - Wu, Tiantian
AU - Lin, Dingbo
AU - Hu, Yaqin
AU - Ye, Xingqian
AU - Tian, Ding
AU - Chai, Wengang
AU - Linhardt, Robert J.
AU - Chen, Shiguo
N1 - Publisher Copyright:
© 2018
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Fucosylated chondroitin sulfate from Isostichopus badionotus (fCS-Ib) is a kind of sulfated polysaccharides with well-repeated structure. In our former publications, fCS-Ib has been reported to be a functional food ingredient with hypoglycemic and antilipemic activities. However, there is no systematic study to investigate the effects of fCS-Ib on metabolic syndromes. In the present study, C57BL/6 mice fed on a high-fat and high sucrose diet (HFSD) for 6 weeks was used to cause metabolic syndromes. The final results showed that fCS-Ib alleviated obesity, hyperlipidemia, hyperglycemia, inflammation, liver steatosis, and adipocyte hypertrophy caused by HFSD. Meanwhile, fCS-Ib showed powerful effects on moderating gut microbiota dysbiosis in the HFSD-fed mice. Supplement of fCS-Ib could reduce ratio of Firmicutes to Bacteroidetes by decreasing abundance of Lachnospiraceae and Allobaculum while increasing abundance of Porphyromonadaceae, Barnesiella, and Bacteroides. Our results showed that fCS-Ib could be further developed as a potential pharmaceutical agent to prevent metabolic syndromes and gut microbiota dysbiosis.
AB - Fucosylated chondroitin sulfate from Isostichopus badionotus (fCS-Ib) is a kind of sulfated polysaccharides with well-repeated structure. In our former publications, fCS-Ib has been reported to be a functional food ingredient with hypoglycemic and antilipemic activities. However, there is no systematic study to investigate the effects of fCS-Ib on metabolic syndromes. In the present study, C57BL/6 mice fed on a high-fat and high sucrose diet (HFSD) for 6 weeks was used to cause metabolic syndromes. The final results showed that fCS-Ib alleviated obesity, hyperlipidemia, hyperglycemia, inflammation, liver steatosis, and adipocyte hypertrophy caused by HFSD. Meanwhile, fCS-Ib showed powerful effects on moderating gut microbiota dysbiosis in the HFSD-fed mice. Supplement of fCS-Ib could reduce ratio of Firmicutes to Bacteroidetes by decreasing abundance of Lachnospiraceae and Allobaculum while increasing abundance of Porphyromonadaceae, Barnesiella, and Bacteroides. Our results showed that fCS-Ib could be further developed as a potential pharmaceutical agent to prevent metabolic syndromes and gut microbiota dysbiosis.
KW - Fucosylated chondroitin sulfate from sea cucumber
KW - Gut microbiota
KW - High-fat and high-sucrose diet
KW - Metabolic syndromes
UR - http://www.scopus.com/inward/record.url?scp=85057382632&partnerID=8YFLogxK
U2 - 10.1016/j.ijbiomac.2018.11.167
DO - 10.1016/j.ijbiomac.2018.11.167
M3 - Article
C2 - 30465844
AN - SCOPUS:85057382632
SN - 0141-8130
VL - 124
SP - 377
EP - 388
JO - International Journal of Biological Macromolecules
JF - International Journal of Biological Macromolecules
ER -